36,120 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Tema Etfs LLC

Tema Etfs LLC acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 36,120 shares of the company’s stock, valued at approximately $1,103,000.

Several other institutional investors and hedge funds have also made changes to their positions in GH. R Squared Ltd purchased a new position in Guardant Health in the 4th quarter valued at about $26,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health in the 4th quarter valued at about $43,000. Kimelman & Baird LLC purchased a new position in Guardant Health in the 4th quarter valued at about $58,000. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after purchasing an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health in the 4th quarter valued at about $61,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Guggenheim restated a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Raymond James restated an “outperform” rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. The Goldman Sachs Group upped their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Canaccord Genuity Group upped their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Finally, Barclays upped their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $52.32.

Guardant Health Stock Up 0.5%

Guardant Health stock opened at $40.67 on Friday. Guardant Health, Inc. has a 52-week low of $20.14 and a 52-week high of $52.92. The firm has a fifty day moving average of $43.81 and a 200-day moving average of $39.64. The firm has a market capitalization of $5.04 billion, a P/E ratio of -11.42 and a beta of 1.49.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. On average, research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity

In other news, CEO Amirali Talasaz sold 106,784 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 107,132 shares of company stock worth $5,249,355. 6.10% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.